Can the early reduction of tumour markers predict outcome in surgically treated sporadic medullary thyroid carcinoma?

2008 ◽  
Vol 393 (5) ◽  
pp. 699-703 ◽  
Author(s):  
Per Bümming ◽  
Håkan Ahlman ◽  
Bengt Nilsson ◽  
Ola Nilsson ◽  
Bo Wängberg ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Tumour Markers ◽  
Sporadic Medullary Thyroid Carcinoma ◽  
Medullary Thyroid

scholarly journals Additive effect of RET polymorphisms on sporadic medullary thyroid carcinoma susceptibility and tumor aggressiveness

2012 ◽  
Vol 166 (5) ◽  
pp. 847-854 ◽  
Author(s):  
L. Ceolin ◽  
D. R. Siqueira ◽  
C. V. Ferreira ◽  
M. Romitti ◽  
S. C. Maia ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Additive Effect ◽  
Tumor Aggressiveness ◽  
Sporadic Medullary Thyroid Carcinoma ◽  
Medullary Thyroid

New Multiple Somatic Mutations in the RET Proto-oncogene Associated with a Sporadic Medullary Thyroid Carcinoma

Thyroid ◽  
2006 ◽  
Vol 16 (3) ◽  
pp. 311-316 ◽  
Author(s):  
Š. Dvořáková ◽  
E. Václavíková ◽  
V. Sýkorová ◽  
J. Dušková ◽  
P. Vlček ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Somatic Mutations ◽  
Sporadic Medullary Thyroid Carcinoma ◽  
Medullary Thyroid

Analysis of alternative mechanisms for RET gene activation in hereditary and sporadic Medullary Thyroid Carcinoma

2010 ◽  
Vol 203 (1) ◽  
pp. 50
Author(s):  
Ciampi Raffaele ◽  
Romei Cristina ◽  
Vivaldi Agnese ◽  
Cosci Barbara ◽  
Tacito Alessia ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Gene Activation ◽  
Sporadic Medullary Thyroid Carcinoma ◽  
Medullary Thyroid ◽  
Ret Gene

scholarly journals Risk Factors for Lateral Lymph Node Metastases in Patients With Sporadic Medullary Thyroid Carcinoma

2020 ◽  
Vol 19 ◽  
pp. 153303382096208
Author(s):  
Xin Wu ◽  
Binglu Li ◽  
Chaoji Zheng ◽  
Wei Liu ◽  
Tao Hong ◽  
...  
Keyword(s):  
Lymph Node ◽  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Lymph Node Metastases ◽  
Lateral Neck ◽  
Lateral Neck Dissection ◽  
Lateral Lymph Node ◽  
Sporadic Medullary Thyroid Carcinoma ◽  
Medullary Thyroid ◽  
Node Metastases

Purpose: Medullary thyroid carcinoma is a rare endocrine malignancy; 75% of patients with this disease have sporadic medullary thyroid carcinoma. While surgery is the only curative treatment, the benefit of prophylactic lateral neck dissection is unclear. This study aimed to analyze the clinicopathological risk factors associated with lateral lymph node metastases and determine the indication for prophylactic lateral neck dissection in patients with sporadic medullary thyroid carcinoma. Methods: The medical records of patients with medullary thyroid carcinoma who were treated at our hospital between January 2002 and January 2020 were retrospectively reviewed; a database of their demographic characteristics, test results, and pathological information was constructed. The relationship between lateral lymph node metastases and clinicopathologic sporadic medullary thyroid carcinoma features were analyzed using univariate and multivariate analyses. Results: Overall, 125 patients with sporadic medullary thyroid carcinoma were included; 47.2% and 39.2% had confirmed central and lateral lymph node metastases, respectively. Univariate and multivariate analyses identified 2 independent factors associated with lateral lymph node metastases: positive central lymph node metastases (odds ratio = 9.764, 95% confidence interval: 2.610–36.523; p = 0.001) and positive lateral lymph nodes on ultrasonography (odds ratio = 101.747, 95% confidence interval: 14.666–705.869; p < 0.001). Conclusion: Medullary thyroid carcinoma is a rare endocrine malignancy. Lymph node metastases are common in patients with sporadic medullary thyroid carcinoma. Prophylactic lateral neck dissection is recommended for patients who exhibit positive central lymph node metastases and/or positive lateral lymph nodes on ultrasonography.

Analysis of Inherited Genetic Variants in ret Proto-Oncogene of Brazilian Patients with Apparently Sporadic Medullary Thyroid Carcinoma

Thyroid ◽  
2006 ◽  
Vol 16 (1) ◽  
pp. 9-15 ◽  
Author(s):  
I.M. Guerrero ◽  
C.H.C. Pessoa ◽  
D.B. Olmedo ◽  
E.R.P. Pontes ◽  
L.C. Matos ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Genetic Variants ◽  
Sporadic Medullary Thyroid Carcinoma ◽  
Medullary Thyroid

scholarly journals Polymorphisms of cell cycle control genes influence the development of sporadic medullary thyroid carcinoma

2014 ◽  
Vol 171 (6) ◽  
pp. 761-767 ◽  
Author(s):  
R B Barbieri ◽  
N E Bufalo ◽  
R Secolin ◽  
L V M Assumpção ◽  
R M B Maciel ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Regression Analysis ◽  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Cell Cycle Control ◽  
Multivariate Logistic Regression Analysis ◽  
Distant Metastases ◽  
Genetic Profile ◽  
Sporadic Medullary Thyroid Carcinoma ◽  
Medullary Thyroid

BackgroundThe role of key cell cycle regulation genes such as, CDKN1B, CDKN2A, CDKN2B, and CDKN2C in sporadic medullary thyroid carcinoma (s-MTC) is still largely unknown.MethodsIn order to evaluate the influence of inherited polymorphisms of these genes on the pathogenesis of s-MTC, we used TaqMan SNP genotyping to examine 45 s-MTC patients carefully matched with 98 controls.ResultsA multivariate logistic regression analysis demonstrated that CDKN1B and CDKN2A genes were related to s-MTC susceptibility. The rs2066827*GT+GG CDKN1B genotype was more frequent in s-MTC patients (62.22%) than in controls (40.21%), increasing the susceptibility to s-MTC (OR=2.47; 95% CI=1.048–5.833; P=0.038). By contrast, the rs11515*CG+GG of CDKN2A gene was more frequent in the controls (32.65%) than in patients (15.56%), reducing the risk for s-MTC (OR=0.174; 95% CI=0.048–0.627; P=0.0075). A stepwise regression analysis indicated that two genotypes together could explain 11% of the total s-MTC risk. In addition, a relationship was found between disease progression and the presence of alterations in the CDKN1A (rs1801270), CDKN2C (rs12885), and CDKN2B (rs1063192) genes. WT rs1801270 CDKN1A patients presented extrathyroidal tumor extension more frequently (92%) than polymorphic CDKN1A rs1801270 patients (50%; P=0.0376). Patients with the WT CDKN2C gene (rs12885) presented larger tumors (2.9±1.8 cm) than polymorphic patients (1.5±0.7 cm; P=0.0324). On the other hand, patients with the polymorphic CDKN2B gene (rs1063192) presented distant metastases (36.3%; P=0.0261).ConclusionIn summary, we demonstrated that CDKN1B and CDKN2A genes are associated with susceptibility, whereas the inherited genetic profile of CDKN1A, CDKN2B, and CDKN2C is associated with aggressive features of tumors. This study suggests that profiling cell cycle genes may help define the risk and characterize s-MTC aggressiveness.

Sign in / Sign up

Export Citation Format

Share Document